A new model, TxGNN, revolutionizes zero-shot drug repurposing by predicting treatments for diseases with no known therapies, offering improved accuracy and trust via interpretable AI explanations.
FDA approves first DNA test for risk of opioid use disorder
Dive Brief: The Food and Drug Administration approved the first test that uses DNA to determine whether someone may have a greater risk of developing
December 20, 2023